EVANSTON, Ill., Nov. 14, 2017 /PRNewswire/ -- Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced the presentation of results from several studies of novel N-methyl-D-aspartate (NMDA) receptor modulators in models of neuropathic pain, post-traumatic stress disorder (PTSD), cognition and traumatic brain injury at Neuroscience 2017, the annual meeting of the Society for Neuroscience, November 11-15, 2017 in Washington, D.C.
"These data demonstrate the diversity of Aptinyx's drug discovery programs and continue to illustrate the broad applicability of modulating NMDA receptors in treating neurologic disorders," said Joseph Moskal, Ph.D., chief scientific officer of Aptinyx.
Enhancement of synaptic plasticity by NYX-2925: Sleep cycle EEG studies in rats (Poster #72.14 / KK18)
NYX-2925, a novel NMDA receptor modulator, reversed cognitive impairment induced by either aging or scopolamine (Poster #129.01 / P8)
The NMDA receptor modulator NYX-2925 demonstrates therapeutic potential in preclinical models for the treatment of neuropathic pain (Poster #374.19 / D34)
NYX-2925 regulates tau dynamics in rat cortical tissues (Poster #395.11 / DD11)
Enhancement of synaptic plasticity by NYX-2925: The role of receptor trafficking and intracellular signaling (Poster #428.23 / UU61)
NYX-783: A novel small molecule NMDA receptor modulator with therapeutic potential for the treatment of post-traumatic stress disorder (Poster #429.02 / UU65)
NYX-2925 promotes GluN2B-PSD95 colocalization and LTP in rat hippocampal neurons (Poster #558.14 / C31)
Aptinyx's chemistry and discovery platform has generated numerous small-molecule modulators of the NMDA receptor, including lead drug candidates NYX-2925 and NYX-783. In studies to date, these molecules have demonstrated high oral bioavailability, diverse NMDA receptor subtype binding profiles, and differentiated efficacy across preclinical models of various nervous system conditions. The company's compounds are designed to enhance synaptic plasticity – or strengthen the network for neural cell communication – a clinically validated mechanism with therapeutic potential in multiple challenging neurologic disorders.
Aptinyx is currently conducting a Phase 2 study of NYX-2925 in patients with neuropathic pain associated with diabetic peripheral neuropathy (DPN), as well as an exploratory study in patients with fibromyalgia. The U.S. Food and Drug Administration has granted Fast Track designation to the development of NYX-2925 for neuropathic pain associated with DPN.
Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and developing transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. Drugs that modulate NMDA receptors in this distinct way have both robust efficacy and exceptionally favorable safety. The company's lead drug candidate, NYX-2925, is in Phase 2 clinical development as a therapy for neuropathic pain, an area of significant unmet need. Aptinyx is also advancing additional compounds from its proprietary chemistry platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.
Chief Business Officer
SOURCE Aptinyx Inc.